Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes

Rebekah L. Robinson, Ashok Kumar Sharma, Shan Bai, Saleh Heneidi, Tae Jin Lee, Sai Karthik Kodeboyina, Nikhil Patel, Shruti Sharma

Research output: Contribution to journalArticle

Abstract

Renal cell carcinomas (RCC) are heterogeneous and can be further classified into three major subtypes including clear cell, papillary and chromophobe. Signal transducer and activator of transcription 3 (STAT3) is commonly hyperactive in many cancers and is associated with cancer cell proliferation, invasion, migration, and angiogenesis. In renal cell carcinoma, increased STAT3 activation is associated with increased metastasis and worse survival outcomes, but clinical trials targeting the STAT3 signaling pathway have shown varying levels of success in different RCC subtypes. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we compared expression of 32 STAT3 regulated genes in 3 RCC subtypes. Our results indicate that STAT3 activation plays the most significant role in clear cell RCC relative to the other subtypes, as half of the evaluated genes were upregulated in this subtype. MMP9, BIRC5, and BCL2 were upregulated and FOS was downregulated in all three subtypes. Several genes including VEGFA, VIM, MYC, ITGB4, ICAM1, MMP1, CCND1, STMN1, TWIST1, and PIM2 had variable expression in RCC subtypes and are potential therapeutic targets for personalized medicine.

Original languageEnglish (US)
Article number00072
JournalFrontiers in Oncology
Volume9
Issue numberFEB
DOIs
StatePublished - Jan 1 2019

Fingerprint

STAT3 Transcription Factor
Transcriptome
Renal Cell Carcinoma
Transcriptional Activation
Genes
Neoplasms
Precision Medicine
Atlases
Down-Regulation
Cell Proliferation
Clinical Trials
Genome
RNA
Neoplasm Metastasis

Keywords

  • Gene expression
  • RNA-seq
  • Renal cell carcinoma
  • STAT3
  • TCGA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes. / Robinson, Rebekah L.; Sharma, Ashok Kumar; Bai, Shan; Heneidi, Saleh; Lee, Tae Jin; Kodeboyina, Sai Karthik; Patel, Nikhil; Sharma, Shruti.

In: Frontiers in Oncology, Vol. 9, No. FEB, 00072, 01.01.2019.

Research output: Contribution to journalArticle

Robinson, Rebekah L. ; Sharma, Ashok Kumar ; Bai, Shan ; Heneidi, Saleh ; Lee, Tae Jin ; Kodeboyina, Sai Karthik ; Patel, Nikhil ; Sharma, Shruti. / Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes. In: Frontiers in Oncology. 2019 ; Vol. 9, No. FEB.
@article{0e2920acc6d847d696eccfb88d823092,
title = "Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes",
abstract = "Renal cell carcinomas (RCC) are heterogeneous and can be further classified into three major subtypes including clear cell, papillary and chromophobe. Signal transducer and activator of transcription 3 (STAT3) is commonly hyperactive in many cancers and is associated with cancer cell proliferation, invasion, migration, and angiogenesis. In renal cell carcinoma, increased STAT3 activation is associated with increased metastasis and worse survival outcomes, but clinical trials targeting the STAT3 signaling pathway have shown varying levels of success in different RCC subtypes. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we compared expression of 32 STAT3 regulated genes in 3 RCC subtypes. Our results indicate that STAT3 activation plays the most significant role in clear cell RCC relative to the other subtypes, as half of the evaluated genes were upregulated in this subtype. MMP9, BIRC5, and BCL2 were upregulated and FOS was downregulated in all three subtypes. Several genes including VEGFA, VIM, MYC, ITGB4, ICAM1, MMP1, CCND1, STMN1, TWIST1, and PIM2 had variable expression in RCC subtypes and are potential therapeutic targets for personalized medicine.",
keywords = "Gene expression, RNA-seq, Renal cell carcinoma, STAT3, TCGA",
author = "Robinson, {Rebekah L.} and Sharma, {Ashok Kumar} and Shan Bai and Saleh Heneidi and Lee, {Tae Jin} and Kodeboyina, {Sai Karthik} and Nikhil Patel and Shruti Sharma",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00072",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes

AU - Robinson, Rebekah L.

AU - Sharma, Ashok Kumar

AU - Bai, Shan

AU - Heneidi, Saleh

AU - Lee, Tae Jin

AU - Kodeboyina, Sai Karthik

AU - Patel, Nikhil

AU - Sharma, Shruti

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Renal cell carcinomas (RCC) are heterogeneous and can be further classified into three major subtypes including clear cell, papillary and chromophobe. Signal transducer and activator of transcription 3 (STAT3) is commonly hyperactive in many cancers and is associated with cancer cell proliferation, invasion, migration, and angiogenesis. In renal cell carcinoma, increased STAT3 activation is associated with increased metastasis and worse survival outcomes, but clinical trials targeting the STAT3 signaling pathway have shown varying levels of success in different RCC subtypes. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we compared expression of 32 STAT3 regulated genes in 3 RCC subtypes. Our results indicate that STAT3 activation plays the most significant role in clear cell RCC relative to the other subtypes, as half of the evaluated genes were upregulated in this subtype. MMP9, BIRC5, and BCL2 were upregulated and FOS was downregulated in all three subtypes. Several genes including VEGFA, VIM, MYC, ITGB4, ICAM1, MMP1, CCND1, STMN1, TWIST1, and PIM2 had variable expression in RCC subtypes and are potential therapeutic targets for personalized medicine.

AB - Renal cell carcinomas (RCC) are heterogeneous and can be further classified into three major subtypes including clear cell, papillary and chromophobe. Signal transducer and activator of transcription 3 (STAT3) is commonly hyperactive in many cancers and is associated with cancer cell proliferation, invasion, migration, and angiogenesis. In renal cell carcinoma, increased STAT3 activation is associated with increased metastasis and worse survival outcomes, but clinical trials targeting the STAT3 signaling pathway have shown varying levels of success in different RCC subtypes. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we compared expression of 32 STAT3 regulated genes in 3 RCC subtypes. Our results indicate that STAT3 activation plays the most significant role in clear cell RCC relative to the other subtypes, as half of the evaluated genes were upregulated in this subtype. MMP9, BIRC5, and BCL2 were upregulated and FOS was downregulated in all three subtypes. Several genes including VEGFA, VIM, MYC, ITGB4, ICAM1, MMP1, CCND1, STMN1, TWIST1, and PIM2 had variable expression in RCC subtypes and are potential therapeutic targets for personalized medicine.

KW - Gene expression

KW - RNA-seq

KW - Renal cell carcinoma

KW - STAT3

KW - TCGA

UR - http://www.scopus.com/inward/record.url?scp=85063272778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063272778&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00072

DO - 10.3389/fonc.2019.00072

M3 - Article

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - FEB

M1 - 00072

ER -